Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
General17 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General20 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News19 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
Business23 hours agoThese ASX 200 shares could rise 55% to 65%